The ability of generating effective humoral immune responses to SARS-CoV-2 infection has not been clarified in lymphoma patients. The study aimed to investigate the antibody (Ab) production after SARS-Cov-2 infection and clarify the factors affecting the Ab generation in these patients. 80 lymphoma patients and 51 healthy controls were included in this prospective observational study. Clinical factors and treatment regimens affecting Ab positive rate (APR) and Ab levels were analyzed by univariate and multivariate methods. The anti-SARS-CoV-2 IgG APR and Ab levels in lymphoma patients were significantly lower than those in healthy controls. Lymphoma patients with COVID-19 vaccination had significantly higher APR and Ab levels compared with those without vaccination. Additionally, the use of dexamethasone for COVID-19 treatment had a negative impact on Ab levels. For the impact of treatment regimens on the APR and Ab levels, the results showed that patients treated with ≥ 6 times CD20 monoclonal Ab (mAb) and patients treated with autologous hematopoietic stem cell transplantation (ASCT) prior to infection produced a statistically lower APR and Ab levels compared with those treated with 1–5 times CD20 mAb and those treated without ASCT, respectively. Furthermore, multiple regression analysis indicated that the number of anti-CD20 treatment was an independent predictor for both APR and Ab levels. Humoral immune response to SARS-CoV-2 infection was impaired in lymphoma patients partly due to anti-CD20 and ASCT treatment. COVID-19 vaccination may be more needed for these patients.

中文翻译：

---

淋巴瘤患者对SARS-CoV-2感染的IgG抗体反应及其影响因素

淋巴瘤患者对 SARS-CoV-2 感染产生有效体液免疫反应的能力尚未明确。该研究旨在调查 SARS-Cov-2 感染后抗体 (Ab) 的产生，并阐明影响这些患者抗体产生的因素。这项前瞻性观察研究纳入了 80 名淋巴瘤患者和 51 名健康对照者。采用单因素和多因素方法分析影响抗体阳性率（APR）和抗体水平的临床因素和治疗方案。淋巴瘤患者的抗 SARS-CoV-2 IgG APR 和 Ab 水平显着低于健康对照。与未接种疫苗的患者相比，接种了 COVID-19 疫苗的淋巴瘤患者的 APR 和 Ab 水平显着升高。此外，使用地塞米松治疗 COVID-19 对抗体水平产生负面影响。对于治疗方案对APR和Ab水平的影响，结果显示，感染前接受≥6倍CD20单克隆抗体（mAb）治疗的患者和感染前接受自体造血干细胞移植（ASCT）治疗的患者产生的APR和Ab水平具有统计学意义较低。分别与接受 1-5 倍 CD20 mAb 治疗的患者和未经 ASCT 治疗的患者相比，抗体水平。此外，多元回归分析表明，抗 CD20 治疗的次数是 APR 和 Ab 水平的独立预测因子。淋巴瘤患者对 SARS-CoV-2 感染的体液免疫反应受损，部分原因是抗 CD20 和 ASCT 治疗。这些患者可能更需要接种 COVID-19 疫苗。